Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Liberty Media Corp. Series C Liberty Formula One-0.89% $29.75B Liberty Media Corp. Series A Liberty Formula One-0.15% $29.75B Liberty Broadband Corp. Cl A-1.36% $11.42B Liberty Broadband Corp. Cl ...

Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders. Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Merck & Co. Inc. 0.85% $248.61B ...

Liberty Media Corp. Series C Liberty Formula One-0.89% $29.75B Liberty Media Corp. Series A Liberty Formula One-0.15% $29.75B ...

Petroleo Brasileiro S/A Ord-1.00% R$503.67B Petroleo Brasileiro S/A Pref-0.62% R$503.67B ...

Intel will report its Q4 earnings after the bell Thursday. Donald Trump's pick for commerce secretary underlined that big and broad tariffs are top of mind both for him and the president during his ...

Bonus Oct 28, 2024 Oct 28, 2024 Sep 05, 2024 Bonus Ratio: 1 share(s) for every 1 shares held Rights May 13, 2020 May 14, 2020 Apr 30, 2020 Rights ratio: 1 share for every 15 held at a price of Rs 1257 ...